KANDLELIT-014: A phase 2 study of MK-1084 as monotherapy and in combination with cetuximab in KRAS G12C-mutant advanced solid tumors.

Authors

• Nehal Lakhani
• Changhoon Yoo
• Cornelia Schuster
• Iván Victoria
• Jeesun Yoon
• Joon Oh Park
• Paul Celano, Greater Baltimore Medical Center (GBMC)
• Tormod Kyrre Guren
• Roman Groisberg
• Chie-Schin Shih
• Thomas Jemielita
• William Bennion McKean

Document Type

Article

Publication Title

Journal of Clinical Oncology

DOI

https://doi.org/10.1200/JCO.2026.44.16_suppl.TPS3185

Publication Date

5-27-2026

Recommended Citation

Nehal J. Lakhani et al. KANDLELIT-014: A phase 2 study of MK-1084 as monotherapy and in combination with cetuximab in KRAS G12C-mutant advanced solid tumors.. J Clin Oncol 44, TPS3185-TPS3185(2026).